A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
Howard Trachtman(University of Michigan), Flavio Vincenti(University of California, San Francisco), James B. Streisand, Marjie Hard, Lorenz Sellin(Heinrich Heine University Düsseldorf), Debbie S. Gipson(University of Michigan–Ann Arbor), Lars Christian Rump(Düsseldorf University Hospital), David Jayne(University of Cambridge), Fernando C. Fervenza(Mayo Clinic), Harm Peters(Charité - Universitätsmedizin Berlin), Jeremy P.W. Heaton, Stefano Rota(University of Bergamo), Peter Heering(Städtisches Klinikum Solingen), Steven Ledbetter, Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research)
Cited by 258
Related Papers
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Avacopan for the Treatment of ANCA-Associated Vasculitis
|New England Journal of Medicine|2021|957
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913